12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ceftaroline acetate regulatory update

FDA's Anti-Infective Drugs Advisory Committee was unanimous that ceftaroline from Forest Labs was a safe and effective treatment for community-acquired bacterial pneumonia (CABP) and complicated skin and skin structure infections (cSSSIs). The panel voted 21-0 and 18-0, respectively.

Panel members were impressed by the robustness of the data...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >